The Dana-Farber/ Harvard Cancer Center (DF/HCC) SPORE in Prostate Cancer Tissue and Pathology Core has provided and will continue to provide collaborating investigators multiple pathology services to support the studies outlined in the four SPORE Research Projects as well as to all current and future Career Development and Development Projects. Through continued collaboration to bring all manner of pathology-based scientific support to all SPORE linked projects, the Tissue and Pathology Core will utilize the multiple technologies of the Center for Molecular Oncologic Pathology. The Core will continue to supervise the frozen tissue and serum bank efforts that have been ongoing for the past 10 years as well as construct from the corresponding archival tissue tissue micorarrays to improve and streamline all immunohistochemical analyses. By performing all aspects of pathologic analysis, the Core will support all tissue based projects and ensure that appropriately classified prostate cancer tissue samples are used and supplied for all tissue-based DNA-, RNA-, and protein-based analyses proposed. In addition, The Core will also provide a variety of services critical to successful molecular analyses of mouse and human prostatic tumors including: histopathologic review and quality control analysis of all tumor samples utilized in experimental studies;cryostat microdissection of frozen tissue samples and slide macrodissection of paraffin-embedded tissues to ensure high neoplastic cellularity for samples utilized in experimental studies;laser capture microdissection (LCM) to provide ultra-pure tumor samples and microscopic sub-populations of cells (such as stem cell populations);performance and analysis of routine immunohistochemical (IHC) stains;optimization of commercially available antibodies for applications in IHC;performance and analysis of a broad range of IHC stains in mouse and human tissues in direct support of the projects;performance of all nuclei acid extractions from all tissue types (fresh frozen and archival FFPE;and Nanostring based transcription analyses using the nCounter assay. Finally, the Core will be extremely flexible in adapting to the best new technologies to meet the scientific goals of the Projects, working to leverage enhanced improvements on all fronts, so as to provide cost savings and improved sample throughput for all methodologies important to all SPORE related projects.

Public Health Relevance

With the varied immunohistochemistry-based, transcriptional-based, and genome-based technologies addressing the scientific aims of the current Prostate SPORE, the presence a centralized lab supporting each project will facilitate a reduction in replicated methodologies, and will help to enhance our knowledge of molecular mechanisms operating in prostate cancer, and ultimately guiding novel diagnostic and therapeutic efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090381-11A1
Application #
8554564
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2001-04-01
Project End
2018-06-30
Budget Start
2013-09-23
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$241,133
Indirect Cost
$86,703
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Preston, Mark A; Batista, Julie L; Wilson, Kathryn M et al. (2016) Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 34:2705-11
Sinnott, Jennifer A; Peisch, Sam; Tyekucheva, Svitlana et al. (2016) Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res :
Yang, Meng; Zu, Ke; Mucci, Lorelei A et al. (2016) Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control 27:1043-7
Thorgeirsson, Tryggvi; Jordahl, Kristina M; Flavin, Richard et al. (2016) Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis 37:262-8
Kelly, Rachel S; Vander Heiden, Matthew G; Giovannucci, Edward et al. (2016) Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev 25:887-906
Gerrin, Sean J; Sowalsky, Adam G; Balk, Steven P et al. (2016) Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. Prostate 76:1227-36
Liu, Xiaming; Han, Weiwei; Gulla, Sarah et al. (2016) Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget 7:1754-64
Ahearn, Thomas U; Tchrakian, Nairi; Wilson, Kathryn M et al. (2016) Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. J Clin Endocrinol Metab 101:2520-7
Li, Zhenfei; Alyamani, Mohammad; Li, Jianneng et al. (2016) Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533:547-51
Xie, Wanling; Yang, Ming; Chan, June et al. (2016) Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate 76:691-9

Showing the most recent 10 out of 217 publications